Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy

Summary

This study aims to determine the effect of Coenzyme Q10 supplementation on conventional therapy of children with heart failure due to idiopathic dilated cardiomyopathy.

Timeline

Start

2006-09

Primary completion

2008-03

Completion

2008-03

Outcome

Mixed primary results

registry MEAN Conezyme Q10: 42.1 (Standard Deviation 14.7) Percentage MEAN Placebo: 37.6 (Standard Deviation 9.7) Percentage analysis (superiority or other test); Conezyme Q10 vs Placebo; p = 0.267; Wilcoxon (Mann-Whitney) NCT02115581 ↗

registry NUMBER Conezyme Q10: 59 Percentage NUMBER Placebo: 19 Percentage analysis (superiority or other test); Conezyme Q10 vs Placebo; p = 0.011; Fisher Exact NCT02115581 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Coenzyme Q10	Other / unclassified	10 mg/kg	—

Indications